Phase 1 clinical data shows Gemin X's GX15-070 improves chronic lymphocytic leukemia

Gemin X Biotechnologies, of Montreal, Canada, says results from a Phase 1/2 clinical trial of GX15-070 (obatoclax) in patients with chronic lymphocytic leukemia (CLL) showed the compound was generally well-tolerated, biologically active and generated clinical improvements.

CLL is a blood cancer that affects an estimated 60,000 Americans and is diagnosed in approximately 8,190 new patients each year in the US.

'These results are very exciting because they illustrate that a compound which selectively restores apoptosis in cancer cells can be both biologically active and well tolerated in humans. The absence of side effects commonly associated with cancer treatments is especially encouraging,' said Dan Giampuzzi, president and ceo of Gemin X. 'Early evidence of activity has been observed despite the use of a sparse administration schedule. Going forward, we will explore more frequent dosing as well as prolonged infusion schedules to determine the optimal Phase 2 dose and schedule,' he said.

Gemin X is currently conducting a Phase 1 clinical trial with GX15-070 in patients with advanced, refractory solid tumours and expects initial results in 2006. The company plans to initiate additional Phase 1 dosing and combination treatment studies as well as the first Phase 2 studies in the first half of 2006.